Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2
Open Access
- 5 August 2009
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 50 (6), 1861-1870
- https://doi.org/10.1002/hep.23214
Abstract
The Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway is one of the key signaling cascades in cholangiocarcinoma (CCA) cells, mediating their resistance to apoptosis. Our aim was to ascertain if sorafenib, a multikinase inhibitor, may also inhibit JAK/STAT signaling and, therefore, be efficacious for CCA. Sorafenib treatment of three human CCA cell lines resulted in Tyr705 phospho‐STAT3 dephosphorylation. Similar results were obtained with the Raf‐kinase inhibitor ZM336372, suggesting sorafenib promotes Tyr705 phospho‐STAT3 dephosphorylation by inhibiting Raf‐kinase activity. Sorafenib treatment enhanced an activating phosphorylation of the phosphatase SHP2. Consistent with this observation, small interfering RNA–mediated knockdown of phosphatase shatterproof 2 (SHP2) inhibited sorafenib‐induced Tyr705 phospho‐STAT3 dephosphorylation. Sorafenib treatment also decreased the expression of Mcl‐1 messenger RNA and protein, a STAT3 transcriptional target, as well as sensitizing CCA cells to tumor necrosis factor–related apoptosis‐inducing ligand (TRAIL)‐mediated apoptosis. In an orthotopic, syngeneic CCA model in rats, sorafenib displayed significant tumor suppression resulting in a survival benefit for treated animals. In this in vivo model, sorafenib also decreased tumor Tyr705 STAT3 phosphorylation and increased tumor cell apoptosis. Conclusion: Sorafenib accelerates STAT3 dephosphorylation by stimulating phosphatase SHP2 activity, sensitizes CCA cells to TRAIL‐mediated apoptosis, and is therapeutic in a syngeneic rat, orthotopic CCA model that mimics human disease. (HEPATOLOGY 2009.)Keywords
This publication has 39 references indexed in Scilit:
- gp130-Mediated Stat3 Activation in Enterocytes Regulates Cell Survival and Cell-Cycle Progression during Colitis-Associated TumorigenesisCancer Cell, 2009
- IL-6 and Stat3 Are Required for Survival of Intestinal Epithelial Cells and Development of Colitis-Associated CancerCancer Cell, 2009
- The STATs of cancer — new molecular targets come of ageNature Reviews Cancer, 2004
- Principles of interleukin (IL)-6-type cytokine signalling and its regulationBiochemical Journal, 2003
- SHP2 and SOCS3 Contribute to Tyr-759-dependent Attenuation of Interleukin-6 Signaling through gp130Published by Elsevier BV ,2003
- Identification of a Nuclear Stat1 Protein Tyrosine PhosphataseMolecular and Cellular Biology, 2002
- Involvement of Tyrosine Phosphatase PTP1D in the Inhibition of Interleukin-6-Induced Stat3 Signaling by α-ThrombinBiochemical and Biophysical Research Communications, 2001
- Regulation of Stat3 Activation by MEK Kinase 1Published by Elsevier BV ,2001
- Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptorsOncogene, 2000
- c-Src Activates the DNA Binding and Transcriptional Activity of Stat3 Molecules: Serine 727 Is Not Required for Transcriptional Activation under Certain CircumstancesBiochemical and Biophysical Research Communications, 1999